MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.970
+0.060 (3.14%)
Feb 6, 2026, 4:00 PM EST - Market closed
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,718,411
Market Cap
75.38M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -5 | -27.78% |
| Dec 31, 2022 | 18 | 9 | 100.00% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 152 |
| MindWalk Holdings | 102 |
| Immunic | 90 |
| XBiotech | 88 |
| PolyPid | 60 |
| iBio, Inc. | 20 |
| MediciNova | 13 |
| Pelthos Therapeutics | 11 |
MAIA News
- 19 days ago - MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum - GlobeNewsWire
- 19 days ago - Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - GlobeNewsWire
- 6 weeks ago - MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings - GlobeNewsWire
- 7 weeks ago - MAIA Biotechnology Announces $1.51 Million Private Placement - GlobeNewsWire
- 2 months ago - MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates - GlobeNewsWire
- 2 months ago - MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach - GlobeNewsWire
- 2 months ago - MAIA Biotechnology Announces Open Market Purchases by CEO and Directors - GlobeNewsWire
- 2 months ago - MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 - GlobeNewsWire